JP2023534924A - ウイルスフソソームを産生するための方法及び組成物 - Google Patents

ウイルスフソソームを産生するための方法及び組成物 Download PDF

Info

Publication number
JP2023534924A
JP2023534924A JP2023500330A JP2023500330A JP2023534924A JP 2023534924 A JP2023534924 A JP 2023534924A JP 2023500330 A JP2023500330 A JP 2023500330A JP 2023500330 A JP2023500330 A JP 2023500330A JP 2023534924 A JP2023534924 A JP 2023534924A
Authority
JP
Japan
Prior art keywords
protein
cells
henipavirus
cell
fusosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534924A5 (https=
JPWO2022010889A5 (https=
Inventor
ベンハー リー，
マイケル トラヴィス ミー，
ジャゲシュ ブイ． シャー，
カイル マーヴィン トルドー，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Publication of JP2023534924A publication Critical patent/JP2023534924A/ja
Publication of JP2023534924A5 publication Critical patent/JP2023534924A5/ja
Publication of JPWO2022010889A5 publication Critical patent/JPWO2022010889A5/ja
Priority to JP2025170166A priority Critical patent/JP2025188163A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023500330A 2020-07-06 2021-07-06 ウイルスフソソームを産生するための方法及び組成物 Pending JP2023534924A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025170166A JP2025188163A (ja) 2020-07-06 2025-10-08 ウイルスフソソームを産生するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048524P 2020-07-06 2020-07-06
US63/048,524 2020-07-06
PCT/US2021/040501 WO2022010889A1 (en) 2020-07-06 2021-07-06 Methods and compositions for producing viral fusosomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025170166A Division JP2025188163A (ja) 2020-07-06 2025-10-08 ウイルスフソソームを産生するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2023534924A true JP2023534924A (ja) 2023-08-15
JP2023534924A5 JP2023534924A5 (https=) 2024-07-17
JPWO2022010889A5 JPWO2022010889A5 (https=) 2024-07-17

Family

ID=79552689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023500330A Pending JP2023534924A (ja) 2020-07-06 2021-07-06 ウイルスフソソームを産生するための方法及び組成物
JP2025170166A Pending JP2025188163A (ja) 2020-07-06 2025-10-08 ウイルスフソソームを産生するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025170166A Pending JP2025188163A (ja) 2020-07-06 2025-10-08 ウイルスフソソームを産生するための方法及び組成物

Country Status (11)

Country Link
US (1) US20240279685A1 (https=)
EP (1) EP4175622A4 (https=)
JP (2) JP2023534924A (https=)
KR (1) KR20230044420A (https=)
CN (1) CN116157116A (https=)
AU (1) AU2021305060A1 (https=)
BR (1) BR112023000151A2 (https=)
CA (1) CA3188810A1 (https=)
IL (1) IL299658A (https=)
MX (1) MX2023000358A (https=)
WO (1) WO2022010889A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018256925B2 (en) 2017-04-28 2024-11-21 Agrospheres, Inc. Compositions and methods for the encapsulation and scalable delivery of agrochemicals
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102578A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018266111B2 (en) * 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102578A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, vol. 86, no. 7, JPN6025028112, 2012, pages 3736 - 3745, ISSN: 0005771749 *
VIROLOGY, vol. 346, JPN6025028111, 2006, pages 251 - 257, ISSN: 0005771748 *

Also Published As

Publication number Publication date
EP4175622A4 (en) 2025-01-29
MX2023000358A (es) 2023-03-14
CA3188810A1 (en) 2022-01-13
IL299658A (en) 2023-03-01
EP4175622A1 (en) 2023-05-10
JP2025188163A (ja) 2025-12-25
KR20230044420A (ko) 2023-04-04
AU2021305060A1 (en) 2023-02-09
US20240279685A1 (en) 2024-08-22
BR112023000151A2 (pt) 2023-03-14
CN116157116A (zh) 2023-05-23
WO2022010889A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7815327B2 (ja) フソソーム組成物およびその使用
US20210353543A1 (en) Targeted lipid particles and compositions and uses thereof
JP2021530985A (ja) フソソームの組成物及びその使用
US20240254168A1 (en) LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USES
US20240279685A1 (en) Methods and compositions for producing viral fusosomes
US20250059239A1 (en) Modified paramyxoviridae fusion glycoproteins
US20240408192A1 (en) Modified paramyxoviridae attachment glycoproteins
CA3120103A1 (en) Fusosome compositions for t cell delivery
US20260098062A1 (en) Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
JP2026067851A (ja) 標的化脂質粒子及び組成物ならびにその使用
WO2024220560A1 (en) Engineered protein g fusogens and related lipid particles and methods thereof
EP4698666A1 (en) Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
CN121443743A (zh) 串联融合剂和相关脂质颗粒
WO2025184529A1 (en) Viral particles with fusogen display and related compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260410